Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Bought by Integral Health Asset Management LLC

Integral Health Asset Management LLC increased its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 80.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 45,000 shares of the biopharmaceutical company's stock after acquiring an additional 20,000 shares during the quarter. Integral Health Asset Management LLC's holdings in Alnylam Pharmaceuticals were worth $10,589,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Capital World Investors boosted its position in shares of Alnylam Pharmaceuticals by 0.6% during the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock worth $3,906,284,000 after acquiring an additional 92,101 shares during the last quarter. Vanguard Group Inc. raised its stake in Alnylam Pharmaceuticals by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company's stock valued at $2,996,296,000 after purchasing an additional 98,303 shares in the last quarter. Capital Research Global Investors raised its stake in Alnylam Pharmaceuticals by 32.9% during the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock valued at $1,639,767,000 after purchasing an additional 1,724,610 shares in the last quarter. Regeneron Pharmaceuticals Inc. purchased a new stake in Alnylam Pharmaceuticals during the fourth quarter valued at $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. raised its stake in Alnylam Pharmaceuticals by 39.7% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 4,384,449 shares of the biopharmaceutical company's stock valued at $1,031,705,000 after purchasing an additional 1,245,195 shares in the last quarter. Institutional investors own 92.97% of the company's stock.

Insiders Place Their Bets

In other news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.56, for a total value of $362,246.40. Following the sale, the executive vice president now directly owns 12,881 shares in the company, valued at approximately $3,240,344.36. This trade represents a 10.06% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Pushkal Garg sold 1,548 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $251.67, for a total transaction of $389,585.16. Following the completion of the sale, the chief marketing officer now owns 11,989 shares in the company, valued at $3,017,271.63. This represents a 11.44% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.50% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Scotiabank upped their price target on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a research note on Monday, March 31st. Royal Bank of Canada upped their price target on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a research note on Friday, March 21st. Needham & Company LLC reaffirmed a "buy" rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 9th. Chardan Capital upped their price target on shares of Alnylam Pharmaceuticals from $300.00 to $325.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. Finally, UBS Group upped their price target on shares of Alnylam Pharmaceuticals from $331.00 to $349.00 and gave the company a "buy" rating in a research note on Friday, May 2nd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and twenty-two have issued a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $319.17.

Alnylam Pharmaceuticals Stock Up 0.7%

Alnylam Pharmaceuticals stock traded up $1.91 during midday trading on Friday, hitting $285.31. 1,193,496 shares of the company's stock were exchanged, compared to its average volume of 911,900. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals, Inc. has a 12 month low of $146.79 and a 12 month high of $304.39. The firm has a 50-day moving average of $253.73 and a two-hundred day moving average of $253.58. The company has a market cap of $37.20 billion, a PE ratio of -131.48 and a beta of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. During the same quarter last year, the firm posted ($0.16) EPS. Alnylam Pharmaceuticals's quarterly revenue was up 20.2% compared to the same quarter last year. As a group, analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.